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httpcense.Abstract Aim of the work: This study aimed to analyze induced sputum in asthmatic patients
under different forms of treatment and study factors that may affect sputum cellularity in asthmatic
patients.
Patients and methods: Eighty asthmatic patients were included. Patients with contra-indication
for sputum induction were excluded. Spirometer, sputum induction, sputum processing, sputum
total cell count, viability, centrifugation, staining and count were done.
Results: Eighty patients were included in the study to investigate induced sputum in asthmatic
patients under different forms of treatment. Patient’s sex 43 (53.8%) male and 37 (46.2%) female
patients were included. Their mean age ± SD was 32.05 ± 10.87 years. Sputum cell indices of asth-
matic patients were 35.22% neutrophilic inﬂammation, 17.81% eosinophilic inﬂammation and the
lymphocytic inﬂammation was 26.48%.
Conclusion: Study concluded that the use of sputum induction as noninvasive measurements of
airway inﬂammation in the diagnosis and management of asthma is very important for every
patient diagnosed with bronchial asthma before starting asthma management and for asthmatic
patients who were not controlled by full asthma management to understand the type of airway
inﬂammation.
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In the healthy human airway there is normally a ﬁne balance
between immune cells, the epithelium, and the host immune
response. Airway inﬂammation in asthma reﬂects a distortion
of this balance and is orchestrated through a complex interplay
between multiple effectors and target components [1]. The
airway inﬂammation in asthma is persistent even through
symptoms are episodic, and the severity of asthma and the
intensity of inﬂammation is not clearly established [2]. Asthmahe Egyptian Society of Chest Diseases and Tuberculosis.
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22 N.R. Mohamed et al.is an inﬂammatory disorder of the airways which involves sev-
eral inﬂammatory cells and multiple mediators that result in
characteristic pathophysiological changes [3].
Some patients with asthma and COPD, particularly those
suffering an acute exacerbation or with severe symptoms can
produce sputum spontaneously. Concerns have been raised
that inhalation of hypertonic saline could in itself alter cell
or marker contents and concentrations in the sputum. Sponta-
neous sputum samples have been shown to contain percentages
of inﬂammatory cells and mediators similar to those in induced
sputum samples [4,5]. Cell viability was signiﬁcantly higher in
induced sputum samples than in spontaneous sputum samples
but there were no signiﬁcant differences in total or differential
cell counts [4]. Quality of cell samples was also poorer in rela-
tion to morphology in spontaneous sputum samples than in in-
duced sputum samples. Prolonged residence of mucus
secretion in an airway could lead to fewer viable cells and less
easy distinction between different types of inﬂammatory cells.
Sputum induction could also result in mobilization of a newer
cell population after an older one. Perhaps the dying popula-
tion of cells has been spontaneously expectorated [4]. In this
respect, induced sputum samples would be preferable to spon-
taneous sputum samples.
Hypertonic saline inhalation can cause bronchoconstriction
in asthmatic subjects [6]. The mechanism of the effect is un-
known but may involve the activation of airway mast cells
or sensory nerve endings [7]. Most investigators use a short-
acting b2-agonist to prevent excessive bronchoconstriction in
asthmatic and COPD subjects in whom sputum is induced
[8] but some do not [6]. Despite pre-treatment with an inhaled
b2-agonist, falls in forced expiratory volume in one second
(FEV1) of greater that 20% have been reported in patients
with asthma and COPD [9].
Indices of airway inﬂammation in induced sputum have
been compared with those obtained using other methods. Fahy
et al. studied markers of inﬂammation and cells in samples ob-
tained by sputum induction, bronchial washing and BAL from
healthy and asthmatic subjects [10]. Their principal ﬁndings
were that concentrations of cells and chemicals were higher
in induced sputum samples than in bronchial washings or
BAL material. Induced sputum samples also contained higher
percentages of neutrophils and eosinophils, and higher concen-
trations of ECP, albumin and mucin-like glycoprotein, proba-
bly because they were less dilute. The constituents of induced
sputum samples more closely resembled those of bronchial
washings than those of BAL material. Bronchial biopsy spec-
imens contained greater numbers of lymphocytes [11]. In some
studies a signiﬁcant correlation has been found between num-
bers of eosinophils in BAL material or bronchial biopsy spec-
imens and numbers of eosinophils in induced sputum samples,
in others no correlation has been found [12,11].
Belda et al. identify a normal range of cell counts in induced
sputum for nonsmoking healthy adults. They show that the
majority of the cells are neutrophils and macrophages, whereas
eosinophils, lymphocytes, and bronchial epithelial cells are
scarce and metachromatic cells (basophils/mast cells) are al-
most absent. They also show a small effect of gender and atopy
on eosinophil counts [13].
The generalization of the normal values reported in this
study took into account the environment within which the
study was conducted as atmospheric pollutants may increase
lung macrophages or neutrophils.Although sputum eosinophilia is a typical feature of asth-
ma, the increasing application of this technique has led to
the recognition that inﬂammation in asthma is more heteroge-
neous than previously believed with the identiﬁcation of non
eosinophilic asthma [14–16]. Non eosinophilic asthma is com-
mon, accounting for 25–55% of corticosteroid-naı¨ve asthmat-
ics; is present across the range of disease severity; and is
repeatable with few subjects with non eosinophilic asthma
acquiring airway eosinophilia [14]. Its identiﬁcation is impor-
tant, as it is associated with a poor response to corticosteroids
[15]. In contrast; asthmatics with sputum eosinophilia have a
favorable response to corticosteroids, even in ex-smokers and
current smokers [17].
Since corticosteroids are the main agents in asthma treat-
ment and there is some evidence that neutrophilic inﬂamma-
tion is associated with a poor response to steroids, Basyigit
et al. also investigated the effects of inhaled steroids on non-
eosinophilic airway inﬂammation. Pavord et al. investigated
the effects of inhaled steroids on spirometric measurements,
symptom scores and induced sputum eosinophil counts in
eosinophilic and non-eosinophilic asthma. They found that
NE asthma is associated with a poor response to inhaled ste-
roids and suggested that sputum eosinophil count is an impor-
tant factor in determining the response to inhaled steroids in
asthma [15].
Patients and methods
Hypothesis
Asthma is a chronic inﬂammatory disorder of the airways
associated with airway obstruction that is often reversible,
either spontaneously or with treatment. Noninvasive methods
for assessing airway inﬂammation are increasingly used in the
investigation and management of asthma. In asthma, the anal-
ysis of cells and mediators in induced sputum has been widely
applied for studying bronchial inﬂammation [18]. Correlation
between type of airway inﬂammation and asthma control
and effect on sputum cellularity can help to guide asthma
treatment. In our study we have tried to study the sputum of
patients with asthma and show the effect of age, sex, smoking
index, residence, ICS, etc on the sputum of asthmatic patients.
Primary research question
What are the different forms of asthma treatment that affect
airway inﬂammation which is measured by: total sputum cell
count, % of sputum eosinophils, and % of sputum
neutrophils?.
Secondary research question
What is the correlation between asthmatic patient pulmonary
function (FVC pre & post bronchodilator, FEV1 pre & post
& change percent and liter, FEV1/FVC ratio pre & post and
PEF pre & post), asthma control and intensity of airway
inﬂammation?.
Study design and subject
Subjects with asthma who attended to outpatient clinic at the
chest department and internal medicine department of the
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study. The study was approved by the hospital’s research eth-
ics broad. All patients provided written informed consent.
Asthma was diagnosed according to the criteria recom-
mended by the Global Initiative for asthma [19]. Asthmatic
subjects had objective diagnosis of asthma with spirometry (in-
crease in FEV1 after 200 mcg of inhaled salbutamol byP12%
and P200 ml with post bronchodilator FEV1/FVCP 70).
Inclusion criteria
All asthmatic patients except patients with contra-indication
for sputum induction.
Exclusion criteria
Contra-indications for sputum induction:
(1) As hypertonic saline causes bronchoconstriction, the
procedure should only be performed after pre-medica-
tion with salbutamol and under medical supervision in
patients with asthma, suspected asthma, or severely
impaired lung function (FEV1 <1 L).
(2) Sputum induction causes severe coughing and the pro-
cedure should not be performed in patients in whom
severe coughing may be harmful. This may include
patients with:
 Haemoptysis of unknown origin.
 Acute respiratory distress.
 Unstable cardiovascular status, (arrhythmias, angina).
 Thoracic, abdominal or cerebral aneurysms.
 Hypoxia (SaO2 less than 90% on room air).
 Lung function impairment (FEV1 less than 1.0 L).
 Pneumothorax.
 Pulmonary emboli.
 Fractured ribs or other chest trauma.
 Recent eye surgery.
 Patients who are unable to follow instructions.
Patients were recruited from the outpatient clinic of chest
department and internal medicine department of the El-Minia
University Hospital, if the inclusion criteria were fulﬁlled.
The patient reports to outpatient clinic were graded accord-
ing to their respiratory symptoms (dyspnoea, wheeze, chest
tightness, sputum volume, sputum purulence, nocturnal
symptoms and earl morning wakening) and precipitating
and reliving factors were also recorded. Spirometry and all
the measurements of airway inﬂammation including blood
measurements and sputum induction was done. An X-ray
of chest, oxygen saturation and electrocardiogram were done,
if clinically indicated.
Methods
 Spirometry: Spirometry was performed using a spirometer
as the best of three consecutive readings within 100 ml,
according to the American Thoracic Standards, before
and 10 min after the inhalation of 200 mcg salbutamol [20].
 Sputum induction: The aim of sputum induction is to collect
an adequate sample of secretions from lower airways in
subjects who do not produce sputum spontaneously
in order to study the features of airway inﬂammation inasthma and other respiratory disorders [21]. Sputum was
induced according to the method of Pizzichini et al. Before
sputum induction, all subjects underwent spirometry, with
FEV1 and vital capacity measurements, before and
10 min after the inhalation of 200 mcg salbutamol by a
metered dose inhaler. Hypertonic saline 4.5% was nebulized
with ultrasonic nebulizer with output set at 1.5 ml/min at
room temperature.The subjects inhaled hypertonic saline
for a 7 min duration, Subjects may be asked to stop inhala-
tion at regular intervals in order to cough up sputum (e.g.,
every 5 min), or to stop only when they feel the urge to
cough [22] and were asked to rinse their mouth with water
before coughing and to blow their nose to avoid salivary
contamination of induced sputum samples. Sputum induc-
tion was discontinued if the FEV1 declined by 20%.
Selected sputum plugs from saliva were then analysed as
described by Pizzichini et al. [5].Methods of sputum processing
 Sputum sample homogenisation: It is recommended that
sputum be processed as soon as possible or within 2 h in
order to ensure optimum cell counting and staining [10,5].
Cells that are incompletely released from mucus tend to
stain darkly, making correct identiﬁcation difﬁcult. DTT
(0.1%), commonly known as 10% sputolysin solution, has
been shown to be more effective at dispersing cells than
phosphate buffered saline (PBS), and has no adverse effects
on cell counts [23].
 Duration and temperature of homogenisation: The duration
and temperature of homogenisation, time ranging 10–
30 min and temperature 4–37 C. It has been demonstrated
that different exposure times to DTT at room temperature
have no effect on the differential cell count (DCC).
 Volume and concentration of added mucolytic: The volume
of mucolytic used during processing of entire expectorate,
although ﬁxed at 1:1, is variable in relation to the ratio of
sputum to saliva, which is unknown. The volume used in
the selected sputum method is ﬁxed [10,22].
 Sample ﬁltration: Filtration through a 48 lm nylon mesh is
commonly used to remove mucus and debris, and is
strongly recommended. A single ﬁltration step results in a
slight reduction in the TCC. However, slide quality is
improved and the DCC remains unchanged [24].
 Total cell count and viability: The TCC is performed manu-
ally using a haemocytometer, and cell viability is deter-
mined by the trypan blue exclusion method [10,22].
 Centrifugation, staining and counts: Centrifugation is neces-
sary to separate sputum cells from the ﬂuid phase. The cen-
trifugal force used to date has a range of 300–1500·g and a
duration of centrifugation of 5–10 min. Then sediments
were stained using Leishmen stain for differential cell count.
Care should be taken to ensure that buffers are at the
appropriate pH (7.1–7.2). This allows accurate characterisa-
tion of cells on the basis of their staining and morphology.
The DCC is determined by counting a minimum of 400
nonsquamous cells and is reported as the relative numbers
of eosinophils, neutrophils, macrophages, lymphocytes
and bronchial epithelial cells, expressed as a percentage of
total nonsquamous cells. The percentage of squamous cells
should always be reported separately [5,23].
Table 3.2 Sputum cell indices of asthmatic patients.
Sputum cells Mean± SD Minimum Maximum
TCC 3225.25 5471.69 100.0 35000.00
Neutrophil % 35.22 27.11 0.0 90.00
Eosinophil % 17.81 17.09 0.0 60.00
Lymphocyte % 26.48 21.63 0.0 90.00
TCC= total cell count.
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 Renal function test.
 C-reactive protein (CRP).
Results
Eighty patients were included in longitudinal study to investi-
gate induced sputum in asthmatic patients under different
forms of treatment. Patient’s clinical characteristics are sum-
marized in Table 3.1. In longitudinal study, 43 (53.8%) male
and 37 (46.2%) female patients were included. Their mean
age was 32.05 (10.87%) years. Their mean FEV1% of pre-
bronchodilator was 60.38 (12.14%). Daily inhaled steroid
ranges from 200 to 800 lg/day budesonide or equivalent [19].
21.3% of asthmatic patients were smokers, 71.3% were non-
smokers and 7.4% were Ex-smokers. As regards residence
35% were urban and 65% were rural. In this study we classi-
ﬁed the patients after treatment according to control of their
disease to controlled patients (20%), partially controlled
(31.2%) and uncontrolled (48.8%). Comparison between
sputum subtypes (eosinophilic, neutrophilic, mixed and non
eosinophilic non neutrophilic) and Asthma control was non-
signiﬁcant. Sputum induction was successful in 72 (90%)
subjects. Inﬂammation was classiﬁed into four types neutro-
philic if neutrophil P65%, eosinophilic if eosinophil P2.4%
[25], mixed (both neutrophilic and eosinophilic) and paucigra-
nulocytic (non neutrophilic and non eosinophilic). Sputum cell
indices are presented in Table 3.2. Fifty-one (63.8%) subjects
had eosinophilic inﬂammation, 8 (10%) had neutrophilic bron-
chitis, 5 (6.2%) had paucigranulocytic, 6 (7.5%) had both andTable 3.1 Demographic data of asthmatic patients (N= 80).
Data are presented as number and their percentage from total
patient number.
Number %
Sex
Male 43 53.8
Female 37 46.2
Residence
Urban 28 35
Rural 52 65
Smoking
Smoker 17 21.3
Non-smoker 57 71.3
Ex-smoker 6 7.4
Asthma control
Controlled 16 20
Partially controlled 25 31.2
Uncontrolled 39 48.8
ICS
Low dose 15 32.6
Moderate dose 31 67.4
High dose 0 0.0
ICS = inhaled corticosteroid.
Total number of patients received ICS (n= 46).
Low dose ICS = 200–400 lg/day budesonide.
Medium dose ICS P400–800 lg/day budesonide.
High dose ICS P800–1600 lg/day budesonide.10 subject was undeﬁned. Sputum induction was successful in
72 (90%) subjects. Inﬂamation was classiﬁed into four types
neutrophilic if neutrophil P65%, eosinophilic if eosinophil
P2.4% [25], mixed (both neutrophilic and eosinophilic) and
paucigranulocytic (non neutrophilic and non eosinophilic).
Sputum cell indices are presented in Table 3.2. Fifty-one
(63.8%) subjects had eosinophilic inﬂamation, 8 (10%) had
neutrophilic bronchitis, 5 (6.2%) had paucigranulocytic, 6
(7.5%) had both and 10 subjects were undeﬁned. Table 3.3
shows mean ages of patients with neutrophilic inﬂammation
higher than eosinophilic inﬂammation. Mean ages of neutro-
philic inﬂammation and eosinophilic inﬂammation were
35.75 ± 9.39 and 32.01 ± 11.173, respectively, but the p-value
was not signiﬁcant (>0.05). Spirometry parameter in eosino-
philic inﬂammation is higher than neutrophilic inﬂammation
except PEF but also showed not signiﬁcant p-value (>0.05).
There was weak (r= 0.14) negative correlation between
neutrophilic inﬂammation (%) and eosinophilic inﬂammation
against pre-bronchodilator FEV1. FEV1 decrease occurred
in the presence of neutrophilic and also in eosinophilic inﬂam-
mation but this correlation is not of signiﬁcant value (p-value
>0.05). r= 0.08 in the case of neutrophilic inﬂammation in
comparison to (0.14) in eosinophilic inﬂammation this means
that FEV1 decreases more with neutrophilic inﬂammation
and both have weak correlation and a statistically insigniﬁcant
p value.
r< 0.25 weak correlation
r= 0.25–0.49 fair correlation
r= 0.25–0.75 moderate correlation
rP 0.75 strong correlation.
In our study asthmatic patients who received ICS showed a
reduction in eosinophilic count (18.8 ± 14.6) when compared
with patients not receiving treatment (37.1 ± 11.2) which is
signiﬁcant (p-value = 0.0001).
Discussion
This study examines the use of sputum cell count in asthmatic
patients under different forms of treatment and the correlation
between asthmatic patients on treatment and others not trea-
ted with sputum and inﬂammatory indices of asthmatic pa-
tients. At the ﬁrst, our demographic data showed that
asthma is common in rural (65%) and 35% in urban and this
is in disagreement with the hygiene hypotheses which suggest
that an environment rich in microbial organisms is beneﬁcial
in building infant resistance to asthma [26]. Cookson reported
that asthma occurs in industrial setting in response to inhaled
proteins such as baker’s ﬂour or to chemical particles [27].
Riedler and colleagues expressed disagreement with our study
Table 3.3 Characteristics of different inﬂammatory subtypes.
Eosinophilic (51) Neutrophilic (8) Mixed (6) Paucigranulocytic (5) p-Value
Age 32.01 ± 11.173 35.75 ± 9.39 27.22 ± 6.94 34.06 ± 11.91 0.4
FEV1 1.91 ± 0.51 1.76 ± 0.39 1.83 ± 0.48 1.71 ± 0.61 0.5
FEV1% 60.69 ± 12.98 56.50 ± 7.89 58.11 ± 8.32 61.73 ± 12.41 0.8
FVC 3.31 ± 0.76 2.87 ± 0.52 3.27 ± 0.91 3.07 ± 0.71 0.5
FVC% 85.75 ± 10.19 76.50 ± 4.12 85.44 ± 7.19 90.06 ± 12.36 0.1
PEF 2.64 ± 1.03 3.15 ± 1.12 2.46 ± 0.58 2.15 ± 1.05 0.2
PEF% 34.94 ± 11.07 40.50 ± 9.25 33.55 ± 9.65 32.60 ± 11.46 0.6
FEV1 = forced expiratory volume in ﬁrst second, PEF = peak expiratory-ﬂow meters, FVC = forced vital capacity.
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with a low prevalence of asthma as exposure to farm animals
and drinking unpasteurized milk are protective in farmer’s
children [28].
Our results showed that asthma is a heterogenous disease
having various subtypes of airway inﬂammation and this is
in agreement with previous studies that identiﬁed different
inﬂammatory phenotypes in subjects with asthma. Lisa et al.
reported that subjects with asthma were classiﬁed as having
nonneutrophilic asthma or neutrophilic asthma. The asthma
(neutrophilic) group had increased systemic inﬂammation
compared with the asthma (nonneutrophilic) and healthy con-
trol groups [29]. Green et al. also demonstrated heterogeneity
in induced sputum cell counts of patients with mild to moder-
ate asthma who have a predominantly neutrophilic airway
inﬂammation and who respond less well to treatment with in-
haled corticosteroids [30]. Simpson et al. showed that asth-
matic patients had four subtypes of airway inﬂammation
neutrophilic, eosinophilic, mixed type and paucigranulocytic
(non eosinophilic non neutrophilic) [31]. One group of our pa-
tients (63.8%) had sputum eosinophilia that in other studies
has been correlated with responsiveness to inhaled corticoste-
roids therapy, severity of airﬂow obstruction and airway
hyperresponsivness [30,32]. Eosinophilic inﬂammation in the
airway mucosa that persists despite the use of high doses of in-
haled corticosteroids or oral corticosteroids has been observed
in several studies [33,34] and has been implicated by Wenzel
and colleagues as a feature of a separate asthma phenotype,
associated with poor asthma prognosis [33]. Other studies have
shown that eosinophilic inﬂammation despite vigorous anti-
asthma treatment is associated with remodeling of the airways,
impaired lung function, and near-fatal asthma attacks [35].
Previous studies have revealed that more than 50% of asth-
matic patients who received no anti-inﬂammatory treatment
have an increased induced sputum eosinophil count [36]. In-
creased eosinophil counts have also been reported in a large
proportion of patients with asthma treated with inhaled corti-
costeroids [37]. Evaluation of the cellular composition of in-
duced sputum in asthmatic patients is of considerable
practical importance [38].
We identiﬁed other subgroups of asthmatic subjects (10%)
that had neutrophilic bronchitis. Subjects with neutrophilic
inﬂammation had more severe airway obstruction and uncon-
trolled asthma. These results agree with results reported by
Shaw and colleagues showing that airway neutrophilia is a
characteristic of more severe asthma and suggest a possible
mechanistic link between airway neutrophils and chronic
airway narrowing in asthma [39]. Woodruff et al. alsodemonstrated low FEV1 in asthmatic patients with neutrophil-
ic bronchitis [40]. Douwes et al. also found that only around
50% of asthma cases was associated with eosinophilic inﬂam-
mation, and that in most other cases asthma was accompanied
by an increase in airway neutrophils and interleukin 8 (IL-8)
[41]. Li et al. reported that a signiﬁcant proportion of asthma
and wheezing illness in both adults and children is associated
with neutrophilic airway inﬂammation and that this pattern
is not limited to individuals with severe symptoms. This raises
important and interesting questions regarding the mechanisms
and consequences of neutrophilic inﬂammation, as well as pre-
senting a novel and inviting therapeutic target [42].
Our study showed all asthmatic patients underwent spirom-
etry with fulﬁlled reversibility criteria post-bronchodilator,
weak positive correlation between eosinophils and (FEV1
and FVC) which are not signiﬁcant (p< 0.05) and negative
correlation with PEF which was also not signiﬁcant
(p< 0.05) and these results disagree with results reported by
Gorska and colleague showing a negative correlation between
the FEV1 increase in the bronchial obstruction reversibility
test and the sputum eosinophil count (r= 0.5, p< 0.05) in
asthmatic patients who had not been treated or received treat-
ment only with bronchodilators during the three-month period
prior to study [43] and results reported by Elbehidy and col-
league showing that there was signiﬁcant negative correlation
between changes in FEV1 and change in eosinophils [44].
There was also weak negative correlation between neutrophilic
bronchitis and (FEV1 and FVC) which also was not signiﬁcant
(p-value <0.05) and these results agree with results reported
by Peleman et al.. Negative correlations between the neutro-
phil count in induced sputum of asthmatic patients vs.
FEV1, and the reduction in annual FEV1 values suggested a
signiﬁcant effect of neutrophils on pulmonary function and
the inﬂuence on the severity of the disease [45].
Asthmatic patients in our study who received ICS showed a
reduction in eosinophilic count (18.8 ± 14.6) when compared
with patients not receiving treatment (37.1 ± 11.2) which is
signiﬁcant (p-value = 0.0001) .This is in agreement with Bacci
et al. who investigated adults, before and after 2 and 4 weeks
of treatment with beclomethasone 500 mg twice daily who
founded that Sputum eosinophilia was associated with
improvement in symptoms, peak expiratory ﬂow and metha-
choline airway responsiveness [17]. Also Elbehidy and col-
league showed that sputum eosinophilia is the best predictor
of steroid response in asthmatics and support the use of
sputum cell counts to guide steroid treatment [44]. This is in
agreement with Brightling who founded strong evidence
that sputum eosinophilia (>3%) is a predictor of clinical
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wisz et al. in a study of children with stable asthma, in whom
the Inhaled corticosteroids (ICS) dose was halved at intervals
of 8 weeks, observed that steroid reduction was successful in
all children with no eosinophils in induced sputum before the
attempted reduction [47]. Our results are in agreement with
Fahy et al. who described the fact that ICSs are regarded the
most effective anti-inﬂammatory therapy for asthma, and sig-
niﬁcantly improve symptoms, inﬂammation, and airway func-
tion, but according to our results this improvement is valuable
only in asthmatic patients with eosinophilic inﬂammatory sub-
type and even may be detrimental in neutrophilic inﬂammation
[48].
Our results are in agreement with Elbehidy and colleagues
who described the fact that ICSs are regarded as the most
effective anti-inﬂammatory therapy for asthma, and signiﬁ-
cantly improve symptoms, inﬂammation, and airway function
[44].
In our study we assessed patients with asthma control in
whom 20% were controlled, 31.2% partially controlled and
49.8% uncontrolled. Patients who were uncontrolled showed
inﬂammatory subtypes in which their eosinophilic bronchitis
results agree with results reported by Anneke and colleagues
who have suggested that patients with refractory eosinophilic
airway inﬂammation represent a separate ‘‘eosinophilic’’ asth-
ma phenotype associated with increased morbidity and a poor
prognosis. Eosinophilic inﬂammation in the airway mucosa
that persists despite the use of high doses of inhaled corticoste-
roids or oral corticosteroids has been observed in several stud-
ies [33] and has been implicated by Wenzel and colleagues as a
feature of a separate asthma phenotype, associated with poor
asthma prognosis [33]. Indeed, studies have shown that eosin-
ophilic inﬂammation despite vigorous antiasthma treatment is
associated with remodeling of the airways, impaired lung func-
tion, and near-fatal asthma attacks [35].
In our study we assessed patients with neutrophilic bronchi-
tis and we found patients with neutrophilic inﬂammation were
eight in number and two of them are controlled and six of
them uncontrolled but had a not signiﬁcant p-value >0.05
and these results agree with results reported by Simpson and
colleagues In adults with stable asthma treated with inhaled
corticosteroids 40% have eosinophilic asthma, whereas
25% have neutrophilic asthma [31]. In the most severe forms
of asthma, sputum neutrophil levels are elevated and nega-
tively correlate with lung function and airﬂow obstruction [31].
Recommendation
The majority of international asthma guidelines have not yet
unequivocally endorsed the use of induced sputum as noninva-
sive measurements of airway inﬂammation in the diagnosis
and management of asthma. We hope induced sputum is rec-
ommended for every patient diagnosed with bronchial asthma
before starting asthma management and for asthmatic patients
who are not controlled by full asthma management to under-
stand the type of airway inﬂammation in all guidelines.
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